Ratiopharm reduces Teva's dependency on Copaxone in Q3
This article was originally published in Scrip
Teva Pharmaceutical Industries' recent acquisition, the German company Ratiopharm for which Teva paid $3.6 billion in August, accounted for 45% of the Israeli firm's net sales growth in the third quarter. Teva's total sales were up by $700 million to $4.3 billion, a 20% increase over the same quarter in 2009. Ratiopharm, Germany's second-largest producer of generics and biosimilar pharmaceuticals, added around $315 million in revenues since Teva acquired it.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.